Phase 2 of the M-E Combination Study compared this recommended combination dose with a 160 mg QD enzalutamide monotherapy—the standard of care for the intended patient population. The primary ...

Phase 2 of the M-E Combination Study compared this recommended combination dose with a 160 mg QD enzalutamide monotherapy-the standard of care for the intended patient population. The primary ...

Phase 2 of the M-E Combination Study compared this recommended combination dose with a 160 mg QD enzalutamide monotherapy-the standard of care for the intended patient population. The primary ...

Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required ...

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn ...

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn ...

masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (iii) the M-E Combination Study, a monotherapy and ...